Family Medicine Doctors in Penn Yan, NY Accepting Medicare

5 Family Medicine doctors found. Showing 1 - 5

Vy Le, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1930 Pre Emption Rd, Penn Yan, NY 14527 Phone: 315-536-0086

Dr. James Michael Bell, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1930 Pre Emption Rd, Penn Yan, NY 14527 Phone: 315-536-0086    Fax: 315-536-4107

Dr. Mary D. Driesch, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 160 Main St, Penn Yan, NY 14527 Phone: 315-536-2752    Fax: 315-536-4005

Dr. Lisa Lynn Walk-reinard, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 207 1/2 Lake St, Penn Yan, NY 14527 Phone: 315-536-3362    Fax: 315-536-6836

Dr. Wayne Steven Strouse, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 108 Kimball Ave, Penn Yan, NY 14527 Phone: 315-536-2273    Fax: 315-531-3056

News Archive

Statins cut the risk of serious infection

According to scientists Cholesterol-lowering drugs, known as statins, can reduce the risk of severe infection in patients suffering from heart disease or stroke.

Takeda receives FDA response regarding NDA for fixed-dose combination of alogliptin and ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).

Majority of Australians do not know the risk factors associated with diabetes

New research conducted by Medibank 24/7 Health Advice Line reveals the majority (97%) of Australians do not know all the major symptoms of diabetes or how many types there are, despite it affecting 3.6 million people nationwide and costing the economy $6 billion per year.

Positive top-line results from Idera's IMO-3100 Phase 2a trial on plaque psoriasis

Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.

Read more Medical News

› Verified 4 days ago